secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001711279-25-000078
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q2 2025 net income $38.3M ($1.29 diluted EPS) on $96M VYJUVEK revenue
--------------------------------------------------------------------------------

- VYJUVEK net product revenue $96.0M in Q2 2025, up from $70.3M in Q2 2024; gross margin 93%.
- Net income $38.3M vs $15.6M YoY; basic EPS $1.33, diluted EPS $1.29.
- Cash and investments $820.8M; FY 2025 non-GAAP R&D+SG&A guidance $150-175M.
- VYJUVEK approved in Japan for DEB patients from birth; launch expected by end of 2025.
- First patient dosed in Phase 3 IOLITE study (KB803 for corneal abrasions in DEB) and Phase 2 EMERALD-1 (KB801 for NK).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/0001711279-25-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/krys-20250804.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer